Glucose-dependent insulinotropic peptide analogs

摘要

1. The compound having the formula (I): where: R is selected from the group consisting of: (D) Tyr; DesNH-Tyr; (D) Phe; DesNH-Phe; (D) Trp; (D) 3Pya; 2-Cl- (D) Phe; 3-Cl- (D) Phe; 4-Cl- (D) Phe; 2-F- (D) Phe; 3-F- (D) Phe; 3,5-DiF (D) Phe and 3,4,5-TriF (D) Phe; R is Lys or Ala; R is Lys or PEGylated Lys; Y is acyl; n is 1 when R is ( D) Tyr; (D) Phe; (D) Trp; (D) 3Pya; 2-CI- (D) Phe; 3-Cl- (D) Phe; 4-Cl- (D) Phe; 2-F- (D) Phe; 3-F- (D) Phe; 3,5-DiF (D) Phe or 3,4,5-TriF (D) Phe; and n is 0 when R is DesNH-Tyr, (D) Phe or DesNH-Phe; or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1, where R is (D) Tyr or DesNH-Tyr. 3. The compound according to claim 1, where R is (D) Tyr. 4. The compound according to claim 1, where R is selected from the group consisting of: (D) Phe; DesNH-Phe; 2-Cl- (D) Phe; 3-CI- (D) Phe; 4-CI- (D) Phe; 2-F- (D) Phe; 3-F- (D) Phe; 3,5-DiF (D) Phe and 3,4,5-TriF (D) Phe. 5. The compound according to claim 1, where R is (D) Trp. 6. The compound according to claim 1, where R is (D) 3Pya. 7. The compound of claim 1, wherein R4 is Lys. A compound according to claim 1, wherein R1 is Ala. The compound according to claim 1, where R is Lys. 10. The compound according to claim 1, where R is a pegylated Lys. 11. The compound of claim 1, wherein R4 is Lys-PEG. The compound of claim 1, wherein R4 is Lys-PEG. A compound according to claim 1, wherein R1 is PEGylated Lys, wherein the PEG moiety has a molecular weight of from about 5,000 to about 40,000 Daltons. A compound according to claim 1, wherein R 1 is PEGylated Lys, wherein the PEG moiety has a molecular weight of from about 10,000 to about 30,000 Daltons. A compound according to claim 1, wherein R1 is a pegylated Lys, wherein the PEG moiety has a molecular weight of from about 15,000 to about 25,000 Daltons. The compound according to claim 1, where R is a pegylated Lys, where the PEG moiety has a molecular weight of about 20,000 Daltons.